Fingerprint
Dive into the research topics of 'Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group
Research output: Contribution to journal › Article › peer-review
66
Scopus
citations